Trial reportJournal of clinical hypertension (Greenwich, Conn.)2004
Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2007Pooled it
- Trial
- Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.Journal of women's health (2002)Trial
- The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.Drug safety · 2015Review
- Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.The European journal of health economics : HEPAC : health economics in prevention and care · 2011Article
- Introducing candesartan 32 mg plus hydrochlorothiazide 25 mg in previously untreated patients with severe essential hypertension.Pragmatic and observational research · 2011Article
- Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).Vascular health and risk management · 2011Article
- Optimizing blood pressure control in patients with chronic kidney disease.Proceedings (Baylor University. Medical Center) · 2010Article
- The epidemiology and management of severe hypertension.Journal of human hypertension · 2010Article
- Review
- Initial combination therapy for rapid and effective control of moderate and severe hypertension.Journal of human hypertension · 2009Review
- The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.Clinical drug investigation · 2009Article
- Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.Journal of human hypertension · 2008Article
- Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?Journal of clinical hypertension (Greenwich, Conn.) · 2008Review
- Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.Drugs · 2008Review
- Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers).Clinical drug investigation · 2008Review
- Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.Vascular health and risk management · 2008Review
- Emerging insights in the first-step use of antihypertensive combination therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2007Review
- Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.Vascular health and risk management · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with severe hypertension are at high risk for cardiovascular events. The authors hypothesized that initial treatment with a combination angiotensin receptor blocker/diuretic agent would be safe and more effective than initial treatment with a single agent for these patients. In this 6-week, double-blind trial, 585 patients were randomized to losartan/hydrochlorothiazide or losartan as monotherapy and titrated as needed at 2-week intervals to reach goal blood pressure (<90 mm Hg). Almost twice as many patients achieved goal at the primary end point of 4 weeks on 50 mg losartan/12.5 mg hydrochlorothiazide vs. the losartan regimen (50-100 mg; p=0.002). Additionally, almost three times as many patients achieved goal blood pressures at 6 weeks (p<0.001). Adverse experiences on losartan/hydrochlorothiazide (43%) were significantly less than with the angiotensin receptor blocker alone (52.6%). This study confirmed the efficacy and tolerability of initial use of a fixed combination of losartan/hydrochlorothiazide vs. losartan without a thiazide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.